The University of Southampton
University of Southampton Institutional Repository

Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?

Bazelier, Marloes T., Gallagher, Arlene M., van Staa, Tjeerd-Pieter, Cooper, Cyrus, Leufkens, Hubert G. M., Vestergaard, Peter and de Vries, Frank (2012) Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs? Pharmacoepidemiology and Drug Safety, 21, (5), pp. 507-514. (doi:10.1002/pds.3234). (PMID:22392882).

Record type: Article

Abstract

PURPOSE:
Clinical and observational studies suggest that use of thiazolidinediones (TZDs) is associated with an increased fracture risk. In addition, type 2 diabetes mellitus (T2DM) is a risk factor for osteoporotic fracture. Our aim was to estimate fracture risks in TZD users and users of other antidiabetic drugs, classified according to proxies of disease severity.

METHODS:
We conducted a population-based cohort study utilizing the Dutch PHARMO database (1998-2008). PHARMO links pharmacy-dispensing data to the National Hospital Registry. Oral antidiabetic users (n = 123,452) were matched 1:4 by year of birth and sex to non-users. Cox proportional hazards models were used to estimate hazard ratios (HRs) of fracture in TZD users. We created a proxy indicator for disease severity. The first stage was defined as current use of either a biguanide or a sulfonylureum, the second stage as current use of a biguanide and a sulfonylureum at the same time, the third stage was assigned to patients using TZDs and the fourth stage to patients using insulin.

RESULTS:
The risk of osteoporotic fracture was increased 1.5-fold (HR 1.49, 95%CI 1.28-1.73) in patients who currently used TZDs (stage 3), and for patients using insulin (stage 4), the risk was increased 1.2-fold (HR 1.24, 1.14-1.36), as compared with controls. In the first and second stages, risks were lower: HR 1.11 (1.06-1.17) for stage 1 and HR 1.03 (0.96-1.11) for stage 2.

CONCLUSIONS:
When observational studies assess risk of fracture in patients with TZDs, the severity of T2DM should be taken into account.

Full text not available from this repository.

More information

e-pub ahead of print date: 6 March 2012
Published date: May 2012
Keywords: thiazolidinediones, type 2 diabetes mellitus, fracture risk, osteoporosis, adverse events
Organisations: Faculty of Health Sciences

Identifiers

Local EPrints ID: 340341
URI: http://eprints.soton.ac.uk/id/eprint/340341
ISSN: 1053-8569
PURE UUID: 70b938d4-f816-48ed-a30f-4e3367b78dcc
ORCID for Cyrus Cooper: ORCID iD orcid.org/0000-0003-3510-0709

Catalogue record

Date deposited: 19 Jun 2012 15:24
Last modified: 18 Jul 2017 05:45

Export record

Altmetrics

Contributors

Author: Marloes T. Bazelier
Author: Arlene M. Gallagher
Author: Tjeerd-Pieter van Staa
Author: Cyrus Cooper ORCID iD
Author: Hubert G. M. Leufkens
Author: Peter Vestergaard
Author: Frank de Vries

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×